What services does JCC Group provide for pharmaceutical and biologics manufacturers?

JCC Group offers end-to-end regulatory consulting services for pharmaceutical and biologics companies, including 21 CFR Part 211 cGMP compliance, Quality Management System (QMS) design, validation strategy, FDA inspection readiness, supplier qualification, data integrity assessments, and harmonization with ICH international standards (Q7, Q8, Q9, Q10, and Q11). Our consultants partner with clients across the full product lifecycle — from facility start-up and clinical-stage manufacturing through commercial production and post-approval changes.

What types of companies does JCC Group work with?

We support a broad spectrum of clients, including emerging biotech startups, contract manufacturers (CMOs/CDMOs), mid-size pharmaceutical companies, global drug manufacturers, biologics and cell & gene therapy developers, and international manufacturers exporting to the U.S. market. Whether you are launching your first product or managing a multi-site global operation, our services scale to fit your needs.

What is 21 CFR Part 211, and who must comply?

21 CFR Part 211 establishes the FDA's Current Good Manufacturing Practice (cGMP) requirements for finished pharmaceuticals. It applies to any company involved in manufacturing, processing, packaging, labeling, or holding human and veterinary drug products distributed in the United States — including drug substance and drug product manufacturers, contract facilities, and repackagers.

How does JCC Group help companies achieve 21 CFR Part 211 compliance?

We provide comprehensive support including cGMP gap assessments, QMS design and implementation, SOP and documentation development, equipment qualification (IQ/OQ/PQ), process and cleaning validation, quality control laboratory compliance, change control programs, CAPA systems, and mock FDA inspections. Our team builds compliance programs tailored to your operations — not generic templates.

Does JCC Group support biologics manufacturers under 21 CFR Part 211?

Yes. While biologics are also governed by 21 CFR Part 600-series regulations, Part 211 still applies to many aspects of biologic drug product manufacturing. We support biologics manufacturers across monoclonal antibodies, recombinant proteins, vaccines, cell and gene therapies, and biosimilars — addressing both small-molecule and large-molecule complexities.

What are ICH guidelines, and why do they matter?

The International Council for Harmonisation (ICH) develops globally recognized standards for pharmaceutical quality, safety, and efficacy. Compliance with ICH guidelines — especially Q7 (API GMP), Q8 (Pharmaceutical Development), Q9 (Quality Risk Management), Q10 (Pharmaceutical Quality System), and Q11 (Drug Substance Development) — is essential for companies seeking global market access and harmonized regulatory approval across the U.S., EU, Japan, and other ICH regions.

How does JCC Group help companies align with ICH standards?

Our consultants integrate ICH principles into every aspect of our consulting work. We design Pharmaceutical Quality Systems aligned with ICH Q10, implement quality risk management frameworks per ICH Q9, support development activities under Q8/Q11, and ensure API manufacturing aligns with ICH Q7 — enabling clients to meet both FDA expectations and global harmonized requirements simultaneously.

Can JCC Group build a Quality Management System (QMS) from scratch?

Absolutely. We design and implement complete Quality Management Systems for new facilities, startups, and companies transitioning from clinical-stage to commercial manufacturing. Our QMS deliverables include Quality Manuals, SOPs, work instructions, forms, Master Production Records, Batch Production Records, change control systems, and integrated documentation control platforms.

Does JCC Group provide ongoing QMS maintenance and support?

Yes. Beyond initial implementation, we offer long-term advisory services to keep your QMS current with evolving regulations, support periodic management reviews, conduct internal audits, manage CAPA effectiveness checks, and provide regulatory intelligence updates. Many clients engage us as their long-term regulatory partner rather than a one-time consultant.

What happens during a mock FDA inspection conducted by JCC Group?

Our mock inspections replicate real FDA methodology — including facility walkthroughs, document reviews, employee interviews, and front-room/back-room dynamics. We assess your operations against 21 CFR Part 211, your QMS, and applicable ICH standards, then deliver a detailed report with prioritized findings, root cause insights, and clear remediation recommendations.

Can JCC Group help if we received a Form 483 or FDA Warning Letter?

Yes — rapid-response remediation is one of our core specialties. Our team conducts immediate root cause investigations, develops comprehensive CAPA plans, drafts written responses that meet FDA expectations, and manages the remediation process from start to finish. We have helped clients successfully close significant findings and restore compliance under tight deadlines.

FDA-PMTA Application - J&J Consulting Group- FDA Regulatory Compliance

FDA-PMTA Application

Expert PMTA Regulatory Support Services

We guide tobacco manufacturers through PMTA preparation, submission, and FDA review using proven regulatory strategies and scientific compliance expertise.

Call for Appoinment

+ 1 (800) 999-7781

99%

Satisfy client

Years of Experience

0 +

PMTA Introduction

What is Premarket of a Tobacco Application ?

A Premarket Tobacco Product Application (PMTA) is required before any new tobacco product can be legally marketed in the United States. The FDA reviews PMTAs to determine whether a product is appropriate for the protection of public health, based on scientific evidence and population impact.

Since the first PMTA authorization in 2015, FDA review standards have become increasingly rigorous. A complete, well-structured submission is critical to approval success.

Overview of PMTAs

Guide to Premarket Tobacco Product Applications (PMTA)

Any person can submit a Premarket Tobacco Product Application (PMTA) for any seeking an FDA marketing order under section 910(b) of the Federal Food, Drug, and Cosmetic (FD&C) Act.

Population Risks

FDA evaluates overall risks and benefits to users and nonusers before authorizing new products.

01/

Current Users

FDA considers if current tobacco users are likely to stop using products with availability.

02/

Non-Users

FDA assesses whether non-users may start using tobacco if the new product launches.

03/

Public Health

Scientific data must demonstrate the product is appropriate for protecting public health nationwide.

04/

30+ years combined regulatory expertise
Successfully submitted hundreds PMTA applications
FDA approvals for new tobacco products
Comprehensive consumer perception studies completed
Expertise in HPHC reporting compliance

Our Achievements

Key milestones andachievements

Years Of Research

0 +

Satisfaction Rate

0 %

Medical Partner

0 +

Process

PMTA Review Process

The PMTA review process includes pre-submission meetings, acceptance review, filing review, substantive scientific evaluation, and post-market reporting compliance.

A voluntary formal meeting between the applicant and FDA to discuss a planned PMTA submission for a tobacco product.

An administrative review that ensures the product falls under Center for Tobacco Products jurisdiction and confirms that the statutory and regulatory requirements of an application are met based upon Section 910 of the FD&C Act and the criteria set forth in § 1114.27(a)(1).

A threshold determination of whether the application contains sufficient information to permit a substantive review. FDA may refuse to file a PMTA if any of the criteria in § 1114.27(b)(1) apply.

FDA evaluation of the scientific information and data in an application, as well as recommendations from the Tobacco Product Scientific Advisory Committee (TPSAC), if the application was referred.

Deficiency letter: Additional information is needed to complete a scientific review. The letter will specify the number of days an applicant has to respond.
Environmental information request letter: FDA made a scientific decision to issue a marketing granted order; however, the applicant is required to provide information for environmental considerations before a marketing granted order can be issued.

Clinical study requires meticulous planning and careful execution. Failure to adhere to well-thought study protocol/regiment, may lead to a waste of resources

Requires applicants to establish and maintain records and make reports that FDA requires as necessary to determine or facilitate a determination of whether there may be grounds to withdraw or temporarily suspend a marketing granted order. Post-market reporting requirements for all products that receive a marketing granted order are set forth in § 1114.41 and FDA may require additional reporting under the terms of a marketing granted order.

Submit PMTA

How to Submit a PMTA

Follow FDA guidelines carefully. Request IAM account, prepare electronically, submit via CTP Portal, or request waiver if needed.

Request IAM Account

Apply for an IAM account if your company does not already have one, enabling secure access to FDA systems.

Prepare Electronically

Complete your PMTA application using the eSubmitter software and the CTP Transmittal Form template for accurate submission.

Submit Online

Once prepared, submit your PMTA online via the CTP Portal for FDA review and consideration.

Step-by-Step Guide to Successful PMTA Submission Process

Get Expert Help

Ready to Navigate the PMTA Process Confidently?

JJCC Group’s regulatory consultants help tobacco product manufacturers prepare, submit, review, and defend successful PMTAs efficiently and effectively.

How to Prepare

Preparation of the Premarket Tobacco Product Applications (PMTAs)

A PMTA must include complete product data, health risk reports, labeling, manufacturing details, compliance evidence, and FDA-required documentation.

Best Compliance with 5 Star

99% Happy Clients

Testimonial

Trusted PMTA Regulatory Experts

Hear from tobacco manufacturers who successfully navigated the PMTA process with JJCC Group’s expert regulatory guidance.

Their PMTA expertise, documentation accuracy, and FDA communication support helped us avoid delays and regulatory setbacks.

Sarah Bennett OWNER

JJCC simplified a complex PMTA process, delivering structured guidance, strong scientific support, and reliable regulatory strategy.

Bts Ashik OWNER

Working with JJCC Group gave us confidence, clarity, and a trusted partner throughout the entire PMTA approval journey process.

Shadin De Manager

Faqs

Frequently Asked Questions

Our PMTA FAQs help manufacturers understand FDA expectations, documentation needs, scientific requirements, review timelines, and post-submission obligations, ensuring confidence throughout the PMTA process and reducing regulatory uncertainty during product approval.

What is a PMTA?

A PMTA is an FDA application required to demonstrate a tobacco product protects public health before legal U.S. marketing approval.

Who must submit PMTA?

Any manufacturer seeking to market new tobacco or vape products in the United States must submit a PMTA.

What data does FDA require?

FDA requires scientific, toxicological, manufacturing, and population impact data proving product safety and public health benefit.

How long PMTA review takes?

PMTA review timelines vary, depending on application completeness, scientific complexity, and FDA review workload and requests.

What causes PMTA rejection?

Incomplete data, poor organization, missing studies, or failure to demonstrate public health protection may lead to denial.